Skip to main content

Advertisement

Table 1 Baseline demographic, laboratory, and clinical features

From: Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

Baseline feature Randomized treatment assignment p-value Historic relapse control
AS + PQ AS-PYR + PQ DHA-PP + PQ AS alone
Subjects 60 60 60 -- 41
Mean age (range) 29.4 (25–45) 28.6 (21–45) 29.5 (23–50) 0.54 27.7 (22–39)
Mean kg weight (range) 69 (55–87) 71 (54–88) 67 (52–88) 0.05 67 (52–90)
Tympanic °C      
Mean 37.1 37.3 37.2 0.37 36.7
Mean g/dL      
Hemoglobin 13.8 13.9 13.5 0.54 14.2
Mean %      
Methemoglobin 1.39 1.42 1.46 0.35 1.48
Median parasites/μL blood (range) 744 (16–7664) 888 (32–6016) 880 (16–9488) 0.94 1408 (32–15248)
WBCs × 103/μL 7051 6886 6945 0.66 7700
Platelets × 103/μL 171 166 161 0.75 167
Glucose mg/dL 106 108 103 0.73 108
Bilirubin mg/dL 1.03 0.97 1.04 0.69 1.08
  1. AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine